Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
This study has been completed.
Study NCT00654108   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received on April 3, 2008.   Last Updated on February 3, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Escherichia Coli Infections
More general conditions related to this trial
Bacterial Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Interventions listed in this trial
Ciprofloxacin 500 mg
Peru-15-pCTB
Placebo
Additional drug interventions recognized in this trial
Ciprofloxacin
More general drug interventions related to this trial
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services